Hookipa Pharma Says Gilead Purchases Addl. 15 Mln Shares Of HOOKIPA For Total Stake Of About 19.4%
(RTTNews) - Immunotherapeutics company Hookipa Pharma Inc. (HOOK) announced Thursday that Gilead Sciences, Inc. (GILD) has purchased 15 million shares of HOOKIPA's common stock for approximately $21.25 million, at a price of $1.4167 per share.
In addition, HOOKIPA has the right, subject to certain terms and conditions, to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises.
The agreement with Gilead replaces the stock purchase agreement that Hookipa entered into with Gilead in 2022.
The transaction closed on December 20, 2023. Following the completion of the stock purchase, Gilead's ownership in HOOKIPA increased to 18.76 million shares, or approximately 19.4% of HOOKIPA's outstanding shares of Common Stock.
read more
Gilead Recalls COVID-19 Drug Veklury For Injection
Foster City, California-based Gilead Sciences, Inc. is recalling one lot of Veklury (remdesivir) for Injection 100 mg/vial for treating COVID-19, to the consumer level, due to the presence of a glass particle, according to the U.S. Food and Drug Administration. The recall involves Veklury (remdesivir 100mg for injection) with NDC 61958-2901-02, lot # 47035CFA and Expiration Date 11/2025.
RTTNews
|
56 days ago
Kite Says Tecartus Shows Prolonged OS In Adults With Refractory B-cell Acute Lymphoblastic Leukemia
Kite, a Gilead Sciences, Inc. Company (GILD), announced Monday updated, four-year overall survival (OS) data from the pivotal ZUMA-3 study evaluating the CAR T-cell therapy Tecartus (brexucabtagene autoleucel) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
RTTNews
|
168 days ago
Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1
Gilead Sciences, Inc. (GILD) announced Friday the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads.
RTTNews
|
207 days ago
Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years
Biopharmaceutical company Nurix Therapeutics, Inc. (NRIX) announced Tuesday that Gilead Sciences, Inc. (GILD) has elected to extend the research term of the companies' ongoing collaboration, originally established in 2019, by an additional two years.
RTTNews
|
231 days ago
Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program
Gilead Sciences, Inc. (GILD) announced Tuesday an agreement with Holon, Israel-based cancer immunotherapy company Compugen Ltd. (CGEN) to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.
RTTNews
|
336 days ago
Gilead Exercises Option To License Nurix's Protein Degrader Molecule NX-0479
Biopharmaceutical companies Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc. (NRIX) announced Monday that Gilead has exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX-0479.
RTTNews
|
610 days ago
HOOKIPA Pharma Promotes Katia Schlienger As Chief Medical Officer
Biopharmaceutical company HOOKIPA Pharma Inc. (HOOK) announced Thursday the promotion of Katia Schlienger, to Chief Medical Officer and the appointment of Malte Peters, to its Board of Directors, both effective January 1, 2023.
RTTNews
|
705 days ago
Gilead Company Kite Says FDA Oks RVV Manufacturing Facility In California For Commercial Production
Biopharmaceutical company Kite, a Gilead Sciences, Inc. (GILD) company, announced Monday that the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.
RTTNews
|
777 days ago
